NEC OncoImmunity Acquires VAXIMM's Neoantigen Vaccine Development Assets

- VAXIMM technology enables fast generation and delivery of personalized T-cell cancer vaccines and may overcome key issues faced by the neoantigen field- NEC OncoImmunity to initiate first clinical trial

Related Keywords

China ,Germany ,Norway ,Japan ,Mannheim ,Baden Wüberg ,Switzerland ,German ,Thomasd Szucs ,Richard Stratford ,Amotoo Nishihara ,Heinz Lubenau ,Nec Ai Drug Development Business ,China Medical System Holdings ,Executive Vice President ,Chief Technology Officer ,Neoantigen Prediction ,Sunstone Life Science ,Oncoimmunity ,Cquires ,Aximm ,Eoantigen ,Vaccine ,Development ,Assets ,